Abstract
Aim: The objective of this work was to investigatethe prognostic role of the HMGN familyin acute myeloid leukemia(AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlasdatabase were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p<0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p<0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p<0.05). HMGNfamilyexpression had no impact on EFS and OS in AML patients receiving allogeneichematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is apotential prognostic indicatorfor AML.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
